ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
ASLN was delisted on the 18th of July, 2024.
22 hedge funds and large institutions have $1.82M invested in ASLAN Pharmaceuticals Limited American Depositary Shares in 2023 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
16% more funds holding
Funds holding: 19 → 22 (+3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
83% less capital invested
Capital invested by funds: $10.5M → $1.82M (-$8.69M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$589K |
| 2 |
SC
Shay Capital
New York
|
+$377K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$293K |
| 4 |
Renaissance Technologies
New York
|
+$131K |
| 5 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$78.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
-$3.57M |
| 2 |
VCIM
Velan Capital Investment Management
Alpharetta,
Georgia
|
-$1.18M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.07M |
| 4 |
Temasek Holdings
Singapore
|
-$302K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$247K |
ASLN Hedge Fund Activity: Q4 2023 in Review
22 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) for Q4 2023, worth a combined $1.82M — down 83% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ASLN positions and 4 closed out — a net gain of 3 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $589K. The largest seller was Tang Capital Management, exiting entirely with an estimated $3.57M sold.
- 22 institutional investors held ASLAN Pharmaceuticals Limited American Depositary Shares (ASLN) as of Q4 2023, up from 19 in Q3 2023.
- Funds reported $1.82M of ASLAN Pharmaceuticals Limited American Depositary Shares stock for Q4 2023, down 83% quarter-over-quarter.
- 7 funds opened new ASLAN Pharmaceuticals Limited American Depositary Shares positions in Q4 2023 and 4 closed out, a net change of +3 holders.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares buyer in Q4 2023 was UBS Group, an estimated $589K added.
- The largest ASLAN Pharmaceuticals Limited American Depositary Shares seller in Q4 2023 was Tang Capital Management, an estimated $3.57M sold.
Based on aggregated 13F filings for Q4 2023.